NJ A1526

Establishes the Psilocybin Behavioral Health Access and Therapy Pilot Program within the New Jersey Department of Health to research psilocybin for treating conditions including substance use disorders, depression, anxiety, and end-of-life psychological distress.

Appropriates $6 million total, with $2 million allocated to each of three hospitals selected from the northern, central, and southern regions of New Jersey.

Creates an 11-member Psychedelic Therapy and Research Advisory Board including healthcare providers, scientists, legal experts, and representatives with experience in Indigenous medicine and veteran mental health care.

Requires the Department of Health to issue a request for proposals within 180 days and select participating hospitals within 60 days thereafter, with all research complying with FDA and DEA regulations.

Mandates reports to the Governor and Legislature after year two of the pilot program with findings on patient outcomes and recommendations for potential statewide therapeutic psilocybin access.